Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Many people with hemophilia A (PwHA) undergo surgery in their lifetime, often because of complications of their disease. Emicizumab is the first bispecific monoclonal antibody prophylactic therapy for PwHA, and its efficacy and safety have been previously demonstrated; however, there is a need to bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruse-Jarres, Rebecca, Peyvandi, Flora, Oldenburg, Johannes, Chang, Tiffany, Chebon, Sammy, Doral, Michelle Y., Croteau, Stacy E., Lambert, Thierry, Kempton, Christine L., Pipe, Steven W., Ko, Richard H., Trzaskoma, Benjamin, Dhalluin, Christophe, Bienz, Nives Selak, Niggli, Markus, Lehle, Michaela, Paz-Priel, Ido, Young, Guy, Jiménez-Yuste, Víctor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768240/
https://www.ncbi.nlm.nih.gov/pubmed/35939785
http://dx.doi.org/10.1182/bloodadvances.2022007458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768240/
https://www.ncbi.nlm.nih.gov/pubmed/35939785
http://dx.doi.org/10.1182/bloodadvances.2022007458

Ejemplares similares